Fig. 1 · Structure

Documents & Downloads

Metolazone

Cat. No. A10584 CAS 17560-51-9
Metolazone and the other thiazide diuretics inhibit the function of the sodium-chloride symporter and prevent sodium and chloride, water as well, from leaving the lumen to enter the tubule cell.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Metolazone-sensitive transport was demonstrated in HEK293S cells expressing human NCC: metolazone reduced NCC-mediated iodide uptake relative to the corresponding condition without metolazone. The experiment supports functional NCC inhibition; it does not establish a metolazone binding pose or an IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

The human NCC transport comparison included wild-type and engineered constructs and a background control (n = 4 independent experiments; mean ± s.d.). NCCcryo1 lacked obvious transport above background, whereas NCCcryo2 retained lower, metolazone-sensitive activity. Bumetanide and DIDS were present in both drug and comparison conditions. [1]

Metolazone-sensitive human NCC transport in HEK293S cells

Cell-based study · HEK293S cells expressing wild-type human NCC or engineered NCC constructs; figure-labelled Control cells [1]

Metolazone reduced iodide uptake in wild-type NCC and NCCchimera cells. NCCcryo2 had lower basal activity but retained a metolazone-sensitive component; NCCcryo1 showed no obvious transport above background. This is a functional inhibition experiment, not a metolazone binding structure or IC50 determination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Iodide uptake with versus without metolazonequalitative transport inhibition Reduced uptake in NCCwt, NCCchimera and NCCcryo2; no obvious NCCcryo1 activity above background. Mean ± s.d.; n = 4 independent experiments.[1]

Literature-Reported Treatment Conditions

Exposure duration
10 min incubation with or without thiazide, followed by 1 h uptake with or without thiazide at room temperature
Method
Hypotonic chloride-free preactivation; radioactive iodide uptake in HEK293S cells
Co-treatment
Both comparison conditions contained 70 μM bumetanide and 100 μM DIDS to inhibit endogenous NKCC1 and other iodide pathways.
Reported limits
Metolazone concentration, vehicle, supplier and stereochemical composition are not specified in the adopted figure/caption and shared uptake assay text; no value borrowed from polythiazide or hydrochlorothiazide experiments.
Methods and source locations

Compound reported in the paper: Metolazone; Compound label in the paper: Metolazone in Extended Data Fig. 1b

Functional evidence for reported metolazone; no Adooq material validation, salt conversion, enantiomer-specific claim or quantitative potency.

Extended Data Fig. 1b and caption; Results, Structure determination; Methods, 125I−-uptake assay

Iodide uptake with versus without metolazone: 125I− uptake for 1 h at room temperature, scintillation counting, total-protein normalization by BCA. Exact bar heights not extracted. — Extended Data Fig. 1b and caption; Results, Structure determination; Methods, 125I−-uptake assay

In Vivo Studies

In anesthetized dogs, a single slow intravenous administration of metolazone at 1.0 mg/kg increased urine flow and urinary electrolyte excretion over 60 min. Urine flow rose from 15.7 ± 3.7 to 38.4 ± 4.3 μL/g·min at 5 min (mean ± S.E.). Potassium excretion also increased. Systemic blood pressure, renal blood flow and GFR showed no significant change in this acute preparation. [2]

Acute renal clearance response to intravenous metolazone in dogs

Animal study · Pentobarbital-anesthetized mongrel dogs of both sexes (11–15 kg), saline-infused clearance preparation [2]

The selected 1.0 mg/kg condition increased urine flow and electrolyte excretion during a 60-min observation period, without significant changes in systemic blood pressure, renal blood flow or GFR. Potassium excretion also increased. Findings are specific to this acute anesthetized preparation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Urine flow after 1.0 mg/kg intravenous metolazoneurine flow 15.7 ± 3.7 before treatment; 38.4 ± 4.3 at 5 min; 36.6 ± 3.8 at 60 min; μL/g·min (mean ± S.E.)[2]
Urinary sodium excretion after 1.0 mg/kg intravenous metolazonesodium excretion rate 3.52 ± 0.88 before treatment; 8.82 ± 0.87 at 5 min; 9.43 ± 1.32 at 60 min; μEq/g·min (mean ± S.E.)[2]
Systemic blood pressure, renal blood flow and glomerular filtration ratereported significance No significant change under the selected 1.0 mg/kg condition.[2]
Urinary potassium excretiondirection Increased, with a smaller response than sodium excretion.[2]

Conditions shared by the study groups

Route
Intravenous, slow infusion
Frequency
Single administration
Treatment course
60 min post-dose observation
Vehicle
0.2 N NaOH; volume varied with dose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Metolazone 1.0 mg/kgThree consecutive 10-min pre-dose clearance periods; slow versus rapid vehicle administration examined separately in Fig. 2.Urine flow and sodium, chloride and potassium excretion increased; no significant BP, RBF or GFR change reported.[2]
Metolazone 1.0 mg/kg
Model: Anesthetized mongrel dogs of both sexes, 11–15 kg; surgically denervated studied kidney
Reported limits: Clearance cohort total n = 17 across three doses. Dose-specific n is not given in Fig. 3/caption; no subgroup n inferred by subtraction. Separate time-matched vehicle clearance group size not specified in the selected description.
Methods and source locations

Compound reported in the paper: Metolazone; Compound label in the paper: Metolazone, Fig. 1

Reported-compound acute dog evidence; no Adooq lot equivalence, chronic efficacy or human dosing inference.

pp. 114–116: Materials and Methods A; Results A; Figs. 2–3; statistical methods p. 115

Urine flow after 1.0 mg/kg intravenous metolazone: Timed urine collection; numerical values from Results A p. 115; Fig. 3A visually checked. — p. 115 Results A; Fig. 3A p. 116; statistics p. 115

Urinary sodium excretion after 1.0 mg/kg intravenous metolazone: Urinary sodium measured by flame photometry; values printed in Results A, not read from curve heights. — pp. 115–116 Results A; Fig. 3B p. 116

Systemic blood pressure, renal blood flow and glomerular filtration rate: Blood pressure and renal blood flow monitoring; GFR from creatinine clearance; paired Student t-test. — p. 115 Results A; Fig. 3A p. 116

Urinary potassium excretion: Flame photometry and timed urine collection; no exact potassium values inferred from Fig. 3B. — p. 116 Results A and Fig. 3B

Metolazone 1.0 mg/kg · pp. 114–116: Materials and Methods A; Results A; Figs. 2–3; statistical methods p. 115

Specifications

Manufacturer Adooq Bioscience
CAS Number 17560-51-9
Formula C16H16ClN3O3S
Molecular Weight 365.8
Synonyms Zaroxolyn; Mykrox; Zytanix
SMILES
CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 68 mg/mL (185.87 mM)
Water Insoluble
Ethanol 7 mg/mL (19.13 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Minrui Fan, Jianxiu Zhang, Chien-Ling Lee, et al. Structure and thiazide inhibition mechanism of the human Na–Cl cotransporter Nature (2023). PMID: 36792826 DOI: 10.1038/s41586-023-05718-0 Source material
  2. [2] Tokihito Yukimura, Masahito Imanishi, Youichi Abe, et al. Diuretic action of metolazone in dogs Japanese Journal of Pharmacology (1979). PMID: 459149 DOI: 10.1254/jjp.29.113 Source material

Added to your cart

View Cart Checkout
Loading...